Bernhard Eclipses $135,000 towards Lymphoma and Leukemia Research with 6th Annual Light The Night Golf Tournament

Donations Fund Lifesaving Research by Leukemia and Lymphoma Society


Bernhard’s 6th annual Light The Night golf tournament was held on Monday, Oct. 25 and all funds raised at the event were donated to the Leukemia and Lymphoma Society. During the tenure of the tournament, Bernhard has raised more than $135,000 for cancer research.

The Leukemia and Lymphoma Society is the largest nonprofit dedicated to blood cancer research in the United States and is the largest funder of cutting-edge research to advance cures. They have invested nearly $1.3 billion in research, leading the nation in advancing breakthroughs in immunotherapy, genomics and personalized medicine.

“We all want to see an end to cancer,” said Ralph Stingo, business unit manager at Bernhard’s Raleigh, N.C. office. “Light The Night is our largest community experience where we partner with companies to bring light to the darkness of cancer and raise funds for our mission.”

Light The Night is a series of fundraising campaigns across the United States funding of research for blood cancer cures. Bernhard continues to support Light The Night by hosting its annual golf tournament and accepting monetary donations to support patients, survivors and their families. This year’s tournament was held at Hasentree Country Club in North Carolina, where over $29,000 was raised.

“Bernhard believes in nurturing strong community contributions and serving surrounding communities as if they are one of our most cherished customers – because they are,” said Alyssa Jaksich, vice president of environmental, social and governance at Bernhard.

Stingo has been a part of the Executive Committee for the North Carolina Lymphoma and Leukemia Society for five years, and leads a team with fellow Bernhard team members each year to manage the logistics of the golf tournament.

“Our mission begins and ends with the ever-powerful word: cure,” said Stingo. “We are focused on curing blood cancers through our three pillars of research, patient access and advocacy.”